OBLN - Obalon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6050
+0.0149 (+2.53%)
At close: 4:00PM EDT

0.6050 0.00 (0.00%)
After hours: 5:57PM EDT

Stock chart is not supported by your current browser
Previous Close0.5901
Open0.6101
Bid0.6070 x 3200
Ask0.6296 x 1800
Day's Range0.5950 - 0.6300
52 Week Range0.3700 - 3.7000
Volume579,221
Avg. Volume5,397,041
Market Cap18.755M
Beta (3Y Monthly)-5.39
PE Ratio (TTM)N/A
EPS (TTM)-1.6310
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.74
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Obalon Obtains Two New U.S. Patents Covering Its Proprietary Intragastric Balloon System

    SAN DIEGO, July 16, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire10 days ago

    Obalon Strengthens Balance Sheet By Raising Additional Capital And Reducing Debt

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has reduced its outstanding debt under a facility with Pacific Western Bank from $20 million to $5 million. Throughout the second quarter of 2019, Obalon raised approximately $8.8 million in gross proceeds through a series of financings including a registered direct equity offering with A.G.P./Alliance Global Partners acting as our financial advisor, the sale of common stock through its equity line of credit with Lincoln Park Capital and an at-the-market (ATM) equity offering through Canaccord Genuity acting as sales agent.

  • GlobeNewswire26 days ago

    Bariatric Medical Institute of Texas Presents Favorable Study Results for Obalon Balloon Administration Using Navigation Device and Touch Dispenser

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that substantial clinical data from a study conducted with 14 clinical sites was presented at Obesity Weekend in Chicago on Friday, June 21st 2019 by the study co-primary investigator, Michael V. Seger, MD, FACS, FASMBS, Bariatric Surgeon at Bariatric Medical Institute (San Antonio, TX). The co-primary endpoints of the Continuous Obalon Balloon Administration Location Tracking (COBALT) Study were met, with 100% correct decision-making for administering and inflating the Obalon Balloon System using the Navigation device instead of X-ray imaging.

  • GlobeNewswirelast month

    Obalon Appoints Bob MacDonald as Chief Retail Officer

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces the appointment of Bob MacDonald to the newly created position of Chief Retail Officer. In this role, Mr. MacDonald will be primarily responsible for establishing Obalon-owned retail clinics focused on weight loss utilizing the Obalon Balloon System. “Bob’s outstanding experience in developing a successful national chain of aesthetic retail medical clinics for Sono Bello is a natural fit for Obalon, as we implement a retail-focused initiative to bring our proven weight loss solution to more patients,” said William J. Plovanic, Obalon’s President and Chief Financial Officer.

  • Benzinga2 months ago

    Obalon Clinches First US Patent For Obesity Treatment Placement System

    Obalon Therapeutics Inc (NASDAQ: OBLN ) shares have continued to be volatile — and that's no surprise, given that most low-float, low-volume stocks are susceptible to trader manipulation. After spiking ...

  • GlobeNewswire2 months ago

    Obalon Announces Issuance of First U.S. Patent Covering Its Proprietary Navigation System

    SAN DIEGO, June 04, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • Hottest Wall Street Stories: What's Up, What's Down
    Zacks2 months ago

    Hottest Wall Street Stories: What's Up, What's Down

    Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.

  • OBALON THERPTCS (OBLN) Stock Sinks As Market Gains: What You Should Know
    Zacks2 months ago

    OBALON THERPTCS (OBLN) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, OBALON THERPTCS (OBLN) closed at $0.68, marking a -0.37% move from the previous day.

  • Benzinga2 months ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • Benzinga2 months ago

    Obalon Management Takes Advantage Of 200% Rally, Announces $3M Offering

    Medical technology company Obalon Therapeutics Inc. (NASDAQ: OBLN ) announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common ...

  • GlobeNewswire2 months ago

    Obalon Therapeutics, Inc. Prices $3,000,000 Registered Direct Offering

    OBALON THERAPEUTICS, INC. (OBLN) (“Obalon” or the “Company”), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced it has entered into definitive agreements with investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $0.60 per share, pursuant to a registered direct offering.  The gross proceeds of the offering will be approximately $3,000,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds for general corporate purposes, including, among other things, working capital, product development, capital expenditures, and other business opportunities.

  • GlobeNewswire2 months ago

    Expanded Clinical Data Set for the Obalon Balloon System Presented at DDW 2019

    SAN DIEGO, May 21, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • OBALON THERPTCS (OBLN) Dips More Than Broader Markets: What You Should Know
    Zacks2 months ago

    OBALON THERPTCS (OBLN) Dips More Than Broader Markets: What You Should Know

    OBALON THERPTCS (OBLN) closed the most recent trading day at $0.42, moving -1.96% from the previous trading session.

  • GlobeNewswire2 months ago

    Obalon Announces Receipt of Delisting Notification Letters from Nasdaq

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written notices from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") informing it that the Company is no longer in compliance with the Nasdaq Listing Rules. On May 15, 2019 the Company received a written notice from Nasdaq notifying the Company that it is not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) based on the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2019, which reported the Company’s stockholders’ equity as $6,518,000, which is below the minimum of $10,000,000 in stockholders’ equity required for continued listing.

  • Will OBALON THERPTCS (OBLN) Report Negative Q1 Earnings? What You Should Know
    Zacks3 months ago

    Will OBALON THERPTCS (OBLN) Report Negative Q1 Earnings? What You Should Know

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Obalon Engages Cowen to Explore Financial and Strategic Alternatives

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives.  As previously announced, Obalon recently undertook an organizational restructuring intended to refocus activities, streamline operations and make more efficient use of cash. With Cowen’s assistance, the Company plans to expand these efforts by exploring a wide range of financial and strategic alternatives that could enhance stockholder value and enable the Company to continue serving other important constituencies, including patients and physicians.

  • GlobeNewswire4 months ago

    Obalon Announces Restructuring to Streamline Operations & Cash Use

    The Company expects the restructuring to reduce operating expenses in the second quarter of 2019 by approximately 35%, after one-time charges of approximately $1.0 million, when compared to the first quarter of 2019.  The changes reduce overall headcount by approximately 50%, including the elimination of Obalon’s direct field sales force and a reduction of headquarters staff.  As a result, the Company expects to transition to a new selling model intended to efficiently use the existing resources to develop the market and drive revenue.  The Company plans to provide more details related to its revised commercial structure and strategy, in addition to expectations around key metrics and updated financial guidance, on its first quarter 2019 earnings call in May. Dr. Huang continued, “The swallowable, gas-filled Obalon Balloon System continues to perform very well clinically, and we have seen accounts that commit to making Obalon a priority in their practice achieve strong results.

  • GlobeNewswire4 months ago

    Obalon Announces Upcoming Conference Presentations

    SAN DIEGO, March 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire5 months ago

    Obalon Announces First Commercial Use of Navigation and Touch Products for Obalon Balloon Administration

    Obalon Therapeutics, Inc. (NASDAQ:OBLN) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve the reliability and ease of balloon administration, and to reduce the costs and logistics for physicians to adopt the Obalon Balloon System as a non-surgical treatment for their patients with obesity. Dr. Shawn Garber of New York Bariatric Group, who performed the first commercial administration using the Obalon Navigation System said, “We have made the Obalon Balloon a standard of care in my practice with outstanding outcomes for patients.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of OBLN earnings conference call or presentation 22-Feb-19 1:30pm GMT

    Q4 2018 Obalon Therapeutics Inc Earnings Call

  • OBALON THERPTCS (OBLN) Reports Q4 Loss, Lags Revenue Estimates
    Zacks5 months ago

    OBALON THERPTCS (OBLN) Reports Q4 Loss, Lags Revenue Estimates

    OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of -25.81% and -3.05%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire5 months ago

    Obalon Announces First Commercial Shipment of its Navigation Balloon Placement System with Touch Inflation Dispenser

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has begun commercial shipment of the Obalon Navigation System  with Touch Inflation Dispenser. Approved by the U.S. Food and Drug Administration in December 2018, the Company’s proprietary and patented Obalon Navigation System utilizes magnetic resonance, rather than x-ray radiation, to image the Obalon Balloon during placement with a dynamic, real-time image of the balloon on a tablet computer screen. The Obalon Touch Inflation Dispenser is designed specifically for use with the Obalon Navigation System to provide an automated, intuitive, and reliable solution for inflation once the balloon is properly placed in the patient’s stomach.

  • GlobeNewswire5 months ago

    Obalon Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN DIEGO, Feb. 22, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • ACCESSWIRE5 months ago

    Obalon Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Obalon Therapeutics, Inc. (NASDAQ: OBLN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 22, 2019 ...

  • How Many Insiders Bought Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?
    Simply Wall St.5 months ago

    How Many Insiders Bought Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...